Cited 4 times in
A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer (KGOG 3044/EBLIN)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.